6 results
Primary Objective:To demonstrate that serelaxin is superior to placebo in reducing CV death in AHF patients during a follow-up period of 180 days.To demonstrate that serelaxin is superior to placebo in reducing worsening heart failure through Day…
Primary:Assess the safety of repeat doses of serelaxin in chronic heart failureSecondary:- Assess the incidence rate of adverse events of special interest, indicative of hypersensitivity reactions- Assess the safety and tolerability of repeated…
A. What are possible causes of MP and what patients variable are asssociated with MP. What is the natural course and prognosis of MP. What is the influence of MP on the quality of life.B. What is the diagnostic value of SSEP en nerve conduction…
Whether injection of corticosteroids with use of ultrasound in the cubital tunnel is effective in reducing the symptoms compared with patients with an ulnar neuropathy treated with an injection of NaCl 0.9 % (placebo). Both groups will get the usual…
Primary ObjectiveTo provide a definitive answer regarding the efficacy of GON-injection as first-line prophylactic therapy in episodic cluster headache, by showing that GON-injection decreases the mean total dose of verapamil needed during the…
ALZ-801 is an oral agent that is being developed as a potential disease modifying treatment for AD. This 78-week Phase 3 study will focus on Early AD subjects who carry the APOE4/4 genotype, and is designed according to current regulatory guidance…